Back to search

University of Peloponesse

Οικονομική αξιολόγηση των ιατρικών παρεμβάσεων για τη θεραπεία των ασθενών με καρκίνο του πνεύμονα στην Ελλάδα

Abstract

dc:description

Introduction: Lung cancer is the leading cause of cancer-related mortality worldwide, with more than 2.2 million new diagnoses and 1.8 million deaths annually. In Greece, approximately 8,583 new cases were recorded in 2022, with non–small cell lung cancer (NSCLC) accounting for about 85% of cases. Advances in the understanding of the molecular biology of NSCLC have led to the development of targeted therapies that act on specific genetic mutations, offering substantial survival benefits.Tyrosine kinase inhibitors (TKIs) for patients with mutations in the epidermal growth factor receptor (EGFR) or in the anaplastic lymphoma kinase (ALK) have radically transformed the therapeutic approach to advanced NSCLC. The median progression-free survival (PFS) with newer-generation TKIs exceeds 18–24 months, while overall survival (OS) has improved substantially. However, the high acquisition cost of these innovative therapies raises serious sustainability concerns for health systems, particularly in countries with constrained resources such as Greece. Despite their clinical importance, there is a marked lack of comprehensive real-world data (RWD) on the economic burden, patterns of use, and real-life clinical outcomes associated with these therapies in Greece. The systematic collection and analysis of such data are critical for evidence-informed decision-making in the context of health technology assessment (HTA), price negotiation, and health policy formulation. Objective: This doctoral dissertation aims to provide a comprehensive and multidimensional assessment of the economic dimension of lung cancer in Greece, with a particular focus on targeted therapies for patients with EGFR- or ALK-positive NSCLC. Specifically, the study seeks: (a) to systematically review and synthesize the scientific literature regarding the economic cost of lung cancer; (b) to estimate the prevalence of patients receiving TKIs for EGFR- or ALK-positive NSCLC in Greece; (c) to analyse real-world prescribing patterns and temporal trends in the use of different TKIs; (d) to assess the pharmaceutical cost of these therapies for the Greek health system over the period 2020–2022; and (e) to formulate specific policy recommendations to improve health data management and strengthen the sustainability of the system. Methods: The research followed a mixed-methods approach, combining a systematic literature review with primary analysis of real-world data. The systematic review was conducted in accordance with the PRISMA 2020 (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines and was registered in the PROSPERO international database (registration number: CRD42023425206). The literature search was performed in PubMed/MEDLINE, Scopus, and ScienceDirect using predefined search terms related to lung cancer and economic cost. Of the 1,234 records initially identified, seven studies ultimately met the predefined inclusion criteria. The quality of the included studies was assessed using the Effective Public Health Practice Project Quality Assessment Tool (EPHPP). For the primary analysis, data from the national electronic prescription database of the e-Government Center for Social Security Services (IDIKA) were used for the period 2020–2022. The analysis focused on identifying patients with EGFR-positive and ALK-positive NSCLC who received first-line TKIs. The dataset included demographic characteristics (age, sex), type of treatment (specific TKI), prescription dates, and diagnosis coded according to the International Classification of Diseases, 10th Revision (ICD-10). The three-year prescribing prevalence was calculated, along with distributions by age group and sex, annual utilization patterns of different TKIs, and total pharmaceutical expenditure. Costs were calculated based on the official prices listed in the national Drug Price Bulletin of the Ministry of Health and the reimbursement decisions of the National Organization for Health Care Services Provision (EOPYY). The statistical analysis was descriptive and included the calculation of means and standard deviations, prevalence estimates with 95% confidence intervals, as well as the estimation of annual cost per patient and total costs per year and by treatment category. Results: Of the 2,110 records initially identified, seven studies ultimately met the predefined inclusion criteria. The systematic literature review revealed a substantial increase in the economic cost of lung cancer internationally over the past decade. The mean annual cost per patient increased approximately fourfold, from €16,000 in 2015 to €58,974 in 2023. Pharmaceutical expenditure accounted for 70–98% of total direct medical costs, underscoring the dominant role of drug costs. There was an almost complete absence of studies capturing indirect costs (productivity loss, informal care), as well as considerable methodological heterogeneity across studies, which limited the feasibility of quantitative synthesis (meta-analysis). Quality assessment using the EPHPP tool classified most studies as being of moderate quality. The real-world analysis based on IDIKA data showed a three-year prescribing prevalence of 11.84 per 100,000 population for EGFR-positive patients and 2.45 per 100,000 for ALK-positive patients. The demographic profile of patients indicated a mean age of 70.9 years for EGFR-positive patients (53% female) and 64.3 years for ALK-positive patients (52% female), confirming the younger age of onset for ALK-positive malignancies. The sex distribution among EGFR-positive patients was consistent with the international literature, which reports a higher frequency of EGFR mutations in women. With respect to prescribing patterns, there was rapid uptake of newer-generation therapies, reflecting the swift incorporation of scientific evidence into clinical practice. Among EGFR-positive patients, osimertinib (a third-generation TKI) increased from 41% of all prescriptions in 2020 to 63% in 2022, progressively replacing first-generation (gefitinib, erlotinib) and second-generation (afatinib) TKIs. Among ALK-positive patients, alectinib (a second-generation TKI) rose dramatically from 0% in 2020 to 68% in 2021, almost completely replacing crizotinib (a first-generation TKI), which decreased from 100% in 2020 to 32% in 2021. This rapid uptake demonstrates alignment of Greek clinical practice with the guidelines of the European Society for Medical Oncology (ESMO) and the Hellenic Society of Medical Oncology. The economic analysis revealed a substantial burden on the health system. Total annual pharmaceutical expenditure for EGFR-TKIs ranged from €11.49 million (2020) to €11.88 million (2022), while for ALK-TKIs it ranged between €3.30 million (2020) and €3.45 million (2022). The mean annual cost per patient increased from €28,024 in 2020 to €31,758 in 2022 for EGFR-positive patients and from €39,220 to €44,609 for ALK-positive patients over the same period. These amounts significantly exceed Greece’s per capita Gross Domestic Product (€19,100 in 2022), corresponding to 1.7 times GDP per capita for EGFR-positive patients and 2.3 times for ALK-positive patients. Conclusion: This doctoral dissertation provides the first nationwide, comprehensive depiction of the economic burden associated with targeted therapies for patients with EGFR- or ALK-positive NSCLC in Greece. The rapid adoption of innovative, newer-generation therapies, in full alignment with international clinical guidelines, demonstrates the high quality of Greek oncological practice and the commitment of the health system to delivering modern, effective care. However, the high per-patient cost—1.7 to 2.3 times the national per capita GDP—highlights a major economic challenge for system sustainability. The relative stabilization of total expenditure over the 2020–2022 period, despite increased use of more expensive agents, reflects the effectiveness of existing regulatory mechanisms. Nonetheless, the continual introduction of newer, even more costly therapies and the potential expansion of therapeutic indications necessitate proactive strategies to safeguard long-term sustainability. The study identified critical structural gaps in health data management: the absence of a national lung cancer registry integrating molecular and clinical data; the lack of interoperability between information systems (IDIKA, hospitals, molecular laboratories); and the inability to systematically capture clinical outcomes and quality of life in real-world settings. The proposed policy recommendations include: (a) establishing a comprehensive national registry with linkage between IDIKA, national health data infrastructures, and hospitals; (b) strengthening universal access to comprehensive genomic profiling; (c) accelerating HTA processes through Joint Clinical Assessments; (d) developing value-based pricing mechanisms with outcome-based managed entry agreements; and (e) systematically incorporating RWD/RWE into decision-making processes. Leveraging European integration initiatives such as DARWIN EU, the European Health Data Space (EHDS), and the EU HTA Regulation, alongside investment in digital infrastructure, human resources, and data governance, are essential prerequisites for the transition to a health system that successfully balances innovation, equity of access, and fiscal sustainability

Degree

thesis:*
Grantor dc:publisher
University of Peloponesse
Year dc:date
2026

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Gourzoulidis, Georgios
  • Γουρζουλίδης, Γεώργιος

Subjects

dc:subject × 18

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/60790

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Gourzoulidis, Georgios; Γουρζουλίδης, Γεώργιος. Οικονομική αξιολόγηση των ιατρικών παρεμβάσεων για τη θεραπεία των ασθενών με καρκίνο του πνεύμονα στην Ελλάδα. University of Peloponesse, 2026. http://hdl.handle.net/10442/hedi/60790